Antipsychotic Drugs Market cover

Antipsychotic Drugs Market by Drugs Class (First Generation [Haldo, Navane, and Others], Second Generation [Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, and Others], Third Generation [Abilify]), Applications (Schizophrenia, Bipolar Disorders, Dementia, Unipolar Depression, and Others), and Regions (Asia Pacific, North America, Latin America, Europe, and Middle East & Africa) - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast 2021 – 2028.

  • Report ID: HC-2319
  • Author: Growth Market Reports
  • Rating: 4.9
  • Total Reviews: 3
  • No. Of Pages: 194
  • Format:
  • Pub. Date: Upcoming
  • Share:

The global antipsychotic drug market size is expected to expand at a considerable CAGR during the forecast period, 2021–2028. The growth of the market is attributed to the increase in incidences of psychotic disorders such as hallucinations, schizophrenia, bipolar disorder, delusions, and severe depression.

Antipsychotic Drugs Market summary

Antipsychotic drugs, also known as neuroleptics tranquilizers, are predominantly used for the treatment of psychosis and psychotic diseases such as delusions, hallucinations, schizophrenia, bipolar disorder and others. Schizophrenia is considered to be the most common and major psychotic disorder, which has a large number of patients across the globe. As per a study by the Anxiety and Depression Association of America, anxiety is the most common mental illness in the US, around 40 million cases in the country were recorded for the group of age 18 and above, or 18.1% of the population per year. Approximately one-half of the total number of patients identified with depression are also detected with an anxiety disorder. The World Health Organization (WHO) has suggested about the formulation of mental health action plan to prevent mental disorders and encourage mental health globally. Furthermore, as per the statistics by WHO, an about 300 million people are suffering from depression whereas 60 million cases are diagnosed with bipolar disorder globally. Children and adults are at high risk of psychiatric illnesses. It is estimated that nearly 44 million American adults suffer from the ill-effects of uneasiness issue.
The COVID-19 pandemic caused several hardship in the global economy, due to the lockdowns and restriction imposed by the governments across the globe. The pandemic had caused negative impact on the market due to large disruption in the production of the drugs and delayed the non-COVID-19 emergency services. However, with the reduced number of the COVID-19 cases, the market has regained its revenue due to wide resumption of the business operations worldwide.

Market Trends, Drivers, Restraints, and Opportunities

  • Heavy investments from key drugs manufacturing organizations for the development of effective drug as well as governments’ initiative to increase the awareness regarding the disorders among the population are driving the market in the near future.
  • Change in daily habits, increased consumption of drugs and alcohol, as well as rising stress life are key reasons for increasing the mental issues among a large number of the global population. This is expected to drive the market growth.
  • Expansion of R&D activities and rapid introduction of novel antipsychotic compounds are bolstering the market growth.
  • Adverse effects such as blurred vision, insomnia, drowsiness, dry mouth, and probability of habit formation are proved to be harmful for the patient’s health. These factors are hampering the market development in the coming years.
  • Rising patent terminations of key brands such as Risperdal, Seroquel, Invega, and Zyprexa, are restricting the market growth.
  • The presence of huge pool of geriatric population who are at high risk of psychosis and rising healthcare awareness are projected to create huge opportunities for the market expansion during the forecast period. 

Scope of the Report

The report on the global antipsychotic drugs market includes an assessment of the market, trends, segments, and regional markets. Overview and dynamics have also been included in the report.

Attributes Details
Report Title Antipsychotic Drugs Market - Global Industry Analysis, Growth, Share, Size, Trends, and Forecast
Base Year 2020
Historic Data 2018–2019
Forecast Period 2021–2028
Segmentation Drugs Class (First Generation [Haldo, Navane, and Others], Second Generation [Invega, Latuda, Seroquel, Risperdal, Zyprexa, Geodon, and Others], Third Generation [Abilify]), and Applications (Schizophrenia, Bipolar Disorders, Dementia, Unipolar Depression, and Others)
Regional Scope Asia Pacific, North America, Latin America, Europe, and Middle East & Africa
Report Coverage Company Share, Market Analysis and Size, Competitive Landscape, Growth Factors, and Trends, and Revenue Forecast
Key Players Covered in the Report Johnson & Johnson; Pfizer, Inc.; Eli Lilly & Co.; Bristol-Myers Squibb; AstraZeneca; Glaxo SmithKline, Plc; and Allergan, Inc.

Market Segment Insights

Second generation segment is expected to grow at a rapid pace

Based on drugs class, the global antipsychotic drugs market is divided into first generation, second generation, and third generation. The first generation segment is further classified into navane, haldo, and others. The second generation segment is segmented into geodon, invega, latuda, zyprexa, seroquel, risperdal, and others while the third generation consists of abilify. The second generation segment is expected to grow at a rapid pace attributed to the high efficacy of the drugs and are more advanced products than the first generation antipsychotics. This class is named as atypical antipsychotics includes sertindole, clozapine, asenapne, paliperidone, olanzapine, risperidone, quetiapine. Meanwhile, the third generation segment is projected to account for a key market share since the drugs are widely used for the maintenance therapy of the disease. Moreover, the drugs generation offer several benefits such as better tolerability and safety, which is contributing to the growth of the segment during the projected period.

Antipsychotic Drugs Market class

Schizophrenia segment is projected to expand at a considerable CAGR

On the basis of applications, the market is segregated into schizophrenia, bipolar disorders, dementia, unipolar depression, and others. The schizophrenia segment is projected to expand at a considerable CAGR owing to the high number of cases across the world. Additionally, improved diagnostics & treatment and high awareness among the population is contributing for the fast growth rate in the near future. Meanwhile, the unipolar disorder segment is anticipated to flourish remarkably in the near future due to the easy diagnosis and increased awareness among the people. Moreover, the wide prevalence of the disorder globally is likely to drive the segment growth.

North America is anticipated to constitute a key market share

In terms of regions, the global antipsychotic drugs market is classified as Asia Pacific, North America, Latin America, Europe, and Middle East & Africa. North America is anticipated to constitute a key market share during the projected period as the region records high number of mental illness patients. As per the report of Anxiety and Depression Association of America in year 2016, approximately 6.7% population of the U.S. with age 18 years and more was suffering from major depression. Such high prevalence of the disorder and improved healthcare services system in the region is anticipated to push the overall market growth.

Antipsychotic Drugs Market region

The Asia Pacific market, however, is estimated to grow at a significant rate in the coming years due to large number of the disorder cases, developing healthcare facilities, and developing new drug approvals in the region. Additionally, the increasing awareness among the population is also a key factor for the market growth in the region.

Segments

Segments Covered in the Report

The global antipsychotic drugs market has been segmented on the basis of

Drugs Class

  • First Generation
    • Haldo
    • Navane
    • Others
  • Second Generation
    • Invega
    • Latuda
    • Seroquel
    • Risperdal
    • Zyprexa
    • Geodon
    • Others
  • Third Generation
    • Abilify

Applications

  • Schizophrenia
  • Bipolar Disorders
  • Dementia
  • Unipolar Depression
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Johnson & Johnson
  • Pfizer, Inc.
  • Eli Lilly & Co.
  • Bristol-Myers Squibb
  • AstraZeneca
  • Glaxo SmithKline, Plc
  • Allergan, Inc.

Competitive Landscape

Key players competing in the global antipsychotic drugs market are Eli Lilly & Co.; Johnson & Johnson; Pfizer, Inc.; Glaxo SmithKline, Plc; Bristol-Myers Squibb; AstraZeneca; and Allergan, Inc.

Antipsychotic Drugs Market keyplayers

1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Antipsychotic Drugs Market Overview
  4.1. Introduction
     4.1.1. Market Taxonomy
     4.1.2. Market Definition
  4.2. Macro-Economic Factors
     4.2.1. Industry Outlook
  4.3. Antipsychotic Drugs Market Dynamics
     4.3.1. Market Drivers
     4.3.2. Market Restraints
     4.3.3. Opportunity
     4.3.4. Market Trends
  4.4. Antipsychotic Drugs Market - Supply Chain
  4.5. Global Antipsychotic Drugs Market Forecast
     4.5.1. Antipsychotic Drugs Market Size (US$ Mn) and Y-o-Y Growth
     4.5.2. Antipsychotic Drugs Market Size (000’ Units) and Y-o-Y Growth
     4.5.3. Antipsychotic Drugs Market Absolute $ Opportunity
5. Global Antipsychotic Drugs Market Analysis and Forecast by Region
  5.1. Market Trends
  5.2. Introduction
     5.2.1. Basis Point Share (BPS) Analysis by Region
     5.2.2. Y-o-Y Growth Projections by Region
  5.3. Antipsychotic Drugs Market Size and Volume Forecast by Region
     5.3.1. North America
     5.3.2. Latin America
     5.3.3. Europe
     5.3.4. Asia Pacific
     5.3.5. Middle East and Africa (MEA)
  5.4. Absolute $ Opportunity Assessment by Region
  5.5. Market Attractiveness/Growth Potential Analysis by Region
  5.6. Global Antipsychotic Drugs Demand Share Forecast, 2019-2026
6. North America Antipsychotic Drugs Market Analysis and Forecast
  6.1. Introduction
     6.1.1. Basis Point Share (BPS) Analysis by Country
     6.1.2. Y-o-Y Growth Projections by Country
  6.2. North America Antipsychotic Drugs Market Size and Volume Forecast by Country
     6.2.1. U.S.
     6.2.2. Canada
  6.3. Absolute $ Opportunity Assessment by Country
  6.4. Market Attractiveness/Growth Potential Analysis
     6.4.1. By Country
     6.4.2. By Product Type
     6.4.3. By Application
  6.5. North America Antipsychotic Drugs Demand Share Forecast, 2019-2026
7. Latin America Antipsychotic Drugs Market Analysis and Forecast
  7.1. Introduction
     7.1.1. Basis Point Share (BPS) Analysis by Country
     7.1.2. Y-o-Y Growth Projections by Country
     7.1.3. Latin America Average Pricing Analysis
  7.2. Latin America Antipsychotic Drugs Market Size and Volume Forecast by Country
      7.2.1. Brazil
      7.2.2. Mexico
      7.2.3. Rest of Latin America
   7.3. Absolute $ Opportunity Assessment by Country
  7.4. Market Attractiveness/Growth Potential Analysis
     7.4.1. By Country
     7.4.2. By Product Type
     7.4.3. By Application
  7.5. Latin America Antipsychotic Drugs Demand Share Forecast, 2019-2026
8. Europe Antipsychotic Drugs Market Analysis and Forecast
  8.1. Introduction
     8.1.1. Basis Point Share (BPS) Analysis by Country
     8.1.2. Y-o-Y Growth Projections by Country
     8.1.3. Europe Average Pricing Analysis
  8.2. Europe Antipsychotic Drugs Market Size and Volume Forecast by Country
     8.2.1. Germany
     8.2.2. France
     8.2.3. Italy
     8.2.4. U.K.
     8.2.5. Spain
     8.2.6. Russia
     8.2.7. Rest of Europe
  8.3. Absolute $ Opportunity Assessment by Country
  8.4. Market Attractiveness/Growth Potential Analysis
     8.4.1. By Country
     8.4.2. By Product Type
     8.4.3. By Application
  8.5. Europe Antipsychotic Drugs Demand Share Forecast, 2019-2026
9. Asia Pacific Antipsychotic Drugs Market Analysis and Forecast
  9.1. Introduction
     9.1.1. Basis Point Share (BPS) Analysis by Country
     9.1.2. Y-o-Y Growth Projections by Country
     9.1.3. Asia Pacific Average Pricing Analysis
  9.2. Asia Pacific Antipsychotic Drugs Market Size and Volume Forecast by Country
     9.2.1. China
     9.2.2. Japan
     9.2.3. South Korea
     9.2.4. India
     9.2.5. Australia
     9.2.6. Rest of Asia Pacific (APAC)
  9.3. Absolute $ Opportunity Assessment by Country
  9.4. Market Attractiveness/Growth Potential Analysis
     9.4.1. By Country
     9.4.2. By Product Type
     9.4.3. By Application
  9.5. Asia Pacific Antipsychotic Drugs Demand Share Forecast, 2019-2026
10. Middle East & Africa Antipsychotic Drugs Market Analysis and Forecast
  10.1. Introduction
     10.1.1. Basis Point Share (BPS) Analysis by Country
     10.1.2. Y-o-Y Growth Projections by Country
     10.1.3. Middle East & Africa Average Pricing Analysis
  10.2. Middle East & Africa Antipsychotic Drugs Market Size and Volume Forecast by Country
     10.2.1. Saudi Arabia
     10.2.2. South Africa
     10.2.3. UAE
     10.2.4. Rest of Middle East & Africa (MEA)
  10.3. Absolute $ Opportunity Assessment by Country
  10.4. Market Attractiveness/Growth Potential Analysis
     10.4.1. By Country
     10.4.2. By Product Type
     10.4.3. By Application
  10.5. Middle East & Africa Antipsychotic Drugs Demand Share Forecast, 2019-2026
11. Competition Landscape
  11.1. Global Antipsychotic Drugs Market: Market Share Analysis
  11.2. Antipsychotic Drugs Distributors and Customers
  11.3. Antipsychotic Drugs Market: Competitive Dashboard
  11.4. Company Profiles (Details: Overview, Financials, Developments, Strategy)
     11.4.1. Johnson & Johnson
     11.4.2. Pfizer, Inc.
     11.4.3. Eli Lilly & Co.
     11.4.4. Bristol-Myers Squibb
     11.4.5. AstraZeneca
     11.4.6. Glaxo SmithKline, Plc
     11.4.7. Allergan, Inc.

Segments Covered in the Report

The global antipsychotic drugs market has been segmented on the basis of

Drugs Class

  • First Generation
    • Haldo
    • Navane
    • Others
  • Second Generation
    • Invega
    • Latuda
    • Seroquel
    • Risperdal
    • Zyprexa
    • Geodon
    • Others
  • Third Generation
    • Abilify

Applications

  • Schizophrenia
  • Bipolar Disorders
  • Dementia
  • Unipolar Depression
  • Others

Regions

  • Asia Pacific
  • North America
  • Latin America
  • Europe
  • Middle East & Africa

Key Players

  • Johnson & Johnson
  • Pfizer, Inc.
  • Eli Lilly & Co.
  • Bristol-Myers Squibb
  • AstraZeneca
  • Glaxo SmithKline, Plc
  • Allergan, Inc.

Key players competing in the global antipsychotic drugs market are Eli Lilly & Co.; Johnson & Johnson; Pfizer, Inc.; Glaxo SmithKline, Plc; Bristol-Myers Squibb; AstraZeneca; and Allergan, Inc.

Antipsychotic Drugs Market keyplayers

Buy Report